Inspire Pharmaceuticals Earnings Conference Call (Q4 2007)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Feb 26 Calls Today's Calls

Call Details Inspire Pharmaceuticals Earnings Conference Call (Q4 2007) Tue, Feb 26, 2008, 10:00 am Eastern Listen to the archived event audio About Inspire Pharmaceuticals (NasdaqGM:ISPH) Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of prescription pharmaceutical products. The company focuses on the therapeutic areas of ophthalmology and respiratory/allergy. Its product portfolio comprises AzaSite, a topical anti-infective product candidate for the treatment of bacterial conjunctivitis. The company's product candidates in clinical development include Prolacria (diquafosol tetrasodium) for the treatment of dry eye disease; Bilastine, a non-sedating oral H1-antihistamine compound for the treatment or prevention of allergic rhinitis; denufosol tetrasodium, an inhaled product candidate for the treatment of cystic fibrosis; Epinastine nasal spray for seasonal allergic rhinitis; and INS115644 for the treatment of glaucoma. It co-promotes Elestat (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis (cyclosporine ophthalmic emulsion) 0.05% for dry eye in the United States under collaborative agreements with Allergan, Inc. Inspire Pharmaceuticals also has collaborative agreements with Boehringer Ingelheim International GmbH; Cystic Fibrosis Foundation Therapeutics, Inc.; FAES Farma, S.A.; InSite Vision Incorporated; Santen Pharmaceutical Co., Ltd.; and Wisconsin Alumni Research Foundation. The company was founded in 1993 and is based in Durham, North Carolina. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings